Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.42), $0.25 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $60 million versus the consensus estimate of $84.9 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.